We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 14 for:    Recruiting Studies | oropharyngeal | Maryland | Phase 2
Previous Study | Return to List | Next Study

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) (SAVER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04609280
Recruitment Status : Recruiting
First Posted : October 30, 2020
Last Update Posted : April 27, 2022
Information provided by (Responsible Party):
Department of Radiation Oncology, University of Maryland, Baltimore

Brief Summary:
This is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell carcinoma undergoing definitive or adjuvant RT.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Oropharynx Cancer Oropharyngeal Squamous Cell Carcinoma Radiation: Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT) Phase 2

Detailed Description:

Patients with human papillomavirus (HPV) or its surrogate marker p16, positive oropharyngeal squamous cell carcinoma (p16+OPSCC) exhibit favorable overall survival (OS) rates of 70-100% at 3 years. These outcomes are dependent on disease burden and patient characteristics and independent of treatment modality. Significant treatment related side effects exist despite advances in radiotherapy (RT) technology, surgical techniques, and supportive care. In addition to common acute toxicities, the favorable OS of patients with p16+OPSCC potentially places them at increased risk for developing long-term treatment-induced side-effects. Therefore, it is important to establish novel management approaches that maintain excellent current clinical outcomes while effectively reducing acute and long-term side effects.

One such approach of limiting RT-induced toxicity is to decrease the amount of normal tissue that receives radiation through judicious reduction of RT treatment volumes. Treatment of elective nodal volumes increases dose to numerous organs at risk (OARs). Patients with well-lateralized tonsil tumors and limited neck disease can effectively be treated with ipsilateral nodal radiotherapy. However, based on recent phase III trials, contralateral (C/L) elective nodal radiation is performed for the majority of patients with p16+OPSCC increasing acute and long-term toxicities. Therefore, judicious data-driven approaches for decreasing the number of elective ipsilateral and contralateral nodal levels treated is necessary to limit RT-induced side effects. This protocol tests the hypothesis that treating only the high-risk sub-volumes of levels II and III would be effective in maintaining regional control in the elective neck while decreasing xerostomia (dry mouth) and dysphagia (swallowing difficulties).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-arm, Single-stage Phase II Trial of Selective Avoidance of Nodal VolumEs at Minimal Risk (SAVER) in the Contralateral Neck of Patients With p16-positive Oropharynx Cancer
Actual Study Start Date : March 1, 2021
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : November 2025

Arm Intervention/treatment
Experimental: Reduced C/L elective nodal volume
All patients will receive the reduced C/L elective nodal volume as described. Treatment will be delivered via IMRT/VMAT or PBPT.
Radiation: Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)
Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.

Primary Outcome Measures :
  1. Elective out-of-field contralateral nodal failure [ Time Frame: 2-years following completion of radiotherapy ]
    Time to failure will be calculated from the date of informed consent until the date of nodal failure in the untreated elective neck sub-volume.

Secondary Outcome Measures :
  1. Grade 2/3 xerostomia [ Time Frame: 2-years following completion of radiotherapy ]
    defined by PRO-CTCAE (patient-reported outcome (PRO) measurement system - Common Terminology Criteria for Adverse Events (CTCAE))

  2. Dysphagia using The M.D. Anderson Dysphagia Inventory (MDADI) [ Time Frame: 2-years following completion of radiotherapy ]
    The M.D. Anderson Dysphagia Inventory is a self-administered questionnaire designed specifically for evaluating the impact of dysphagia on the Quality of Life (QOL) of patients with head and neck cancer.

  3. PEG-tube rate [ Time Frame: 2-years following completion of radiotherapy ]
    Percutaneous endoscopic gastrostomy (PEG)-tube rate

  4. Overall survival [ Time Frame: 2-years following completion of radiotherapy ]
  5. Progression-free survival [ Time Frame: 2-years following completion of radiotherapy ]
  6. Locoregional control [ Time Frame: 2-years following completion of radiotherapy ]
  7. Incidence of pulmonary metastases [ Time Frame: 2-years following completion of radiotherapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Is there pathologically (histologically or cytologically) proven diagnosis of p16+ squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx (tonsil or base of tongue)? Note: Cytologic diagnosis from a cervical lymph node (from a paraffin block, not from smears) is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage).
  2. Does the patient require elective contralateral radiotherapy in the definitive or adjuvant setting (i.e. base of tongue primary or tonsil with base of tongue invasion, soft palate invasion, or medialized as defined by > 1/3 of the distance from the tonsil to the midline of the soft palate?
  3. Does the patient have clinical stage T1-4, N0, N1 or N3, and M0 disease (AJCC 8th edition) as defined by physical examination and appropriate imaging (PET/CT preferred, CT neck with IV contrast with CT chest without contrast as recommended alternative to PET/CT)?
  4. Was a general history and physical examination performed by a radiation oncologist, medical oncologist, or head and neck surgeon within 60 days prior to registration?
  5. Was the patient's Zubrod Performance Status 0-1 within 30 days prior to registration?
  6. Is the patient ≥ 18 years of age?
  7. For women of childbearing potential, was a serum pregnancy test completed within 2 weeks of initiation or radiotherapy?
  8. If yes, was the serum pregnancy test negative?
  9. If a woman of child-bearing potential or sexually active male, is the patient willing to use effective contraception throughout their participation in the treatment phase of the study and at least 180 days following the last study treatment.
  10. Did the patient provide study specific informed consent prior to study entry, including consent for mandatory submission of tissue for required p16 review?

Exclusion Criteria:

  1. Does the patient have cancer considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), nasopharynx, hypopharynx, or larynx?
  2. Does the patient have a carcinoma of the neck of unknown primary origin?
  3. Does the patient have distant metastasis?
  4. Does the patient have prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years?
  5. Did the patient have prior systemic chemotherapy for the study cancer (prior chemotherapy for a different cancer is allowable)?
  6. Did the patient have prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields?
  7. Did the patient have prior surgery of the head and neck excluding superficial removal of cutaneous skin malignancies?
  8. Is the patient homeless?
  9. Does the patient have an active drug or alcohol dependency?
  10. Is the patient pregnant or nursing (an exception will be made for nursing patients that are not receiving chemotherapy)?
  11. Radiographic evidence of contralateral nodal disease as described below. 1) Max standardized uptake value (SUV) greater than 3.0, or 2) Short-axis diameter is > 1.5 cm for level II nodes, > 0.8 cm for retropharyngeal node, or > 1.0 cm for level III, IV, or V, or 3) Central necrosis or heterogeneous enhancement

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04609280

Layout table for location contacts
Contact: Matthew Witek, MD 410-328-6080 matthew.witek@umm.edu
Contact: Kelly Kitzmiller, BS 4103695264 kelly.kitzmiller@umm.edu

Layout table for location information
United States, Maryland
Maryland Proton Treatment Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Kelly Kitzmiller    410-369-5246    kelly.kitzmiller@umm.edu   
UMMC Recruiting
Baltimore, Maryland, United States, 21201
Contact: Kelly Kitzmiller, BS    410-369-5246    kelly.kitzmiller@umm.edu   
University of Maryland Greenebaum Cancer Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Kelly Kitzmiller, BS    410-369-5246    kelly.kitzmiller@umm.edu   
Upper Chesapeake Health Recruiting
Bel Air, Maryland, United States, 21014
Contact: Linda Romar, BS    443-643-1877    lromar@umm.edu   
Central Maryland Radiation Oncology Recruiting
Columbia, Maryland, United States, 21044
Contact: Kelly Kitzmiller    410-369-5246    kelly.kitzmiller@umm.edu   
Baltimore Washington Medical Center Recruiting
Glen Burnie, Maryland, United States, 21061
Contact: Pilar Strycula       P.Strycula@umm.edu   
Contact: Pilar         
Sponsors and Collaborators
University of Maryland, Baltimore
Layout table for investigator information
Principal Investigator: Matthew Witek, MD University of Maryland/Maryland Proton Treatment Center
Layout table for additonal information
Responsible Party: Department of Radiation Oncology, Principal Investigator, University of Maryland, Baltimore
ClinicalTrials.gov Identifier: NCT04609280    
Other Study ID Numbers: HP-00093439
First Posted: October 30, 2020    Key Record Dates
Last Update Posted: April 27, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Department of Radiation Oncology, University of Maryland, Baltimore:
Head and Neck Cancer
Oropharynx Cancer
Oropharyngeal Squamous Cell Carcinoma
Proton Therapy
Photon Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Oropharyngeal Neoplasms
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases